Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIA

NCT04595565 is registered in ClinicalTrials.gov with GBG Forschungs GmbH as lead sponsor.

NCT NCT04595565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04595565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIA
Lead sponsor
GBG Forschungs GmbH
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 28, 2020
Completion date
March 30, 2029
Enrollment
1,332 (estimated)
Sites
163

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer, triple negative breast cancer